Vaccines
hepatitis A
VIRUS, HEPATITIS A
Inactivated SARS-CoV-2 vaccine (CoronaVac), 23-valent pneumococcal polysaccharide vaccine (PPV23) and inactivated hepatitis A vaccine used in this trial were manufactured by Sinovac Biotech Ltd. and approved by the China National Medical Products Administration (NMPA). CoronaVac is an inactivated COVID-19 vaccine. Each dose contains 600SU inactivated virus in 0.5 mL of aluminum hydroxide solution. The 23-valent pneumococcal polysaccharide vaccine contains 23 serotypes of pneumococcal capsular polysaccharide, each of which was 25 μg per dose (0.5 mL). The inactivated hepatitis A (HepA) vaccine contains 500 SU inactivated hepatitis A virus per dose in 1 mL of aluminum hydroxide solution.